

Type 2 Diabetes in New Jersey

Addressing the devastating impact of type 2 diabetes in New Jersey

Type 2 Diabetes in New Jersey

- ❖ 700,000 New Jerseyans are currently living with diabetes.
- New Jersey ranks 3rd in the nation for obesity among low-income children ages two to five, 16.6% of whom are obese.
- New Jersey faces challenges in both prevention of type 2 diabetes and treatment and management of the disease.

Diabetes Prevention

- ❖ Type 2 diabetes is closely linked with obesity. New Jersey must address obesity not only to prevent the incidence of type 2 diabetes and other chronic diseases, but also to mitigate the consequences of type 2 diabetes once individuals are diagnosed with the disease.
- ♦ 61.5% of New Jersey adults (~5.5 million people) were overweight or obese as of 2011. Almost 50% of those overweight or obese adults (~2.75 million people) had pre-diabetes. Approximately 25% of Americans with pre-diabetes are expected to develop diabetes within three to five years of diagnosis (~700,000 people).

Diabetes Management

- ❖ Type 2 diabetes is difficult to manage effectively, and mismanaged diabetes can lead to particularly debilitating physical effects: damaged blood vessels, heart attacks, strokes, blindness, liver disease, certain kinds of cancer, kidney failure, bone fractures, and amputations.
- Effective management can prevent these devastating complications.

The Costs of Type 2 Diabetes

- New Jersey must act quickly to prevent a **doubling** of diabetes in New Jersey. Diabetes not only affects the health and daily lives of New Jerseyans but costs the state more money as each year passes.
- ❖ In 2010, the total annual diabetes cost for New Jersey was **\$9.3 billion dollars**, of which \$6.6 billion dollars were for medical costs and \$2.7 billion for nonmedical costs.
- By 2025, the number of people affected by diabetes in New Jersey is projected to double, and its cost to the state is projected to reach \$14.5 billion, including lost productivity. New Jersey cannot afford to let these trends continue.

FOR MORE INFORMATION, CONTACT:

The Center for Health Law and Policy Innovation | Email: chlpi@law.harvard.edu